These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21673355)

  • 1. Cervical cancer prevention through cytologic and human papillomavirus DNA screening in Hong Kong Chinese women.
    Wu J
    Hong Kong Med J; 2011 Jun; 17(3 Suppl 3):20-4. PubMed ID: 21673355
    [No Abstract]   [Full Text] [Related]  

  • 2. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
    Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S
    Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
    Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of HPV testing on cervical cancer screening].
    Li G
    Zhonghua Fu Chan Ke Za Zhi; 2015 Apr; 50(4):241-5. PubMed ID: 26080933
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Lynge E; Rebolj M
    J Natl Cancer Inst; 2010 May; 102(10):739; author reply 739-40. PubMed ID: 20360534
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study.
    Shi JF; Canfell K; Lew JB; Zhao FH; Legood R; Ning Y; Simonella L; Ma L; Kang YJ; Zhang YZ; Smith MA; Chen JF; Feng XX; Qiao YL
    BMC Cancer; 2011 Jun; 11():239. PubMed ID: 21668946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
    Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
    BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
    Kim JJ; Wright TC; Goldie SJ
    JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, São Paulo, Brazil.
    Levi JE; Martins TR; Longatto-Filho A; Cohen DD; Cury L; Fuza LM; Villa LL; Eluf-Neto J
    Cancer Prev Res (Phila); 2019 Aug; 12(8):539-546. PubMed ID: 31189569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and costs of using HPV testing to screen for cervical cancer.
    Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
    JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Menstrual pad, a cervical cancer screening tool, a population-based study in rural India.
    Budukh A; Palayekar V; Maheshwari A; Deodhar K; Purwar P; Bagal S; Vadigoppula A; Lokhande M; Panse N; Dikshit R; Badwe R
    Eur J Cancer Prev; 2018 Nov; 27(6):546-552. PubMed ID: 28704213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.
    Felix JC; Lacey MJ; Miller JD; Lenhart GM; Spitzer M; Kulkarni R
    J Womens Health (Larchmt); 2016 Jun; 25(6):606-16. PubMed ID: 27023044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing participation in cervical cancer screening: telephone contact with long-term non-attendees in Sweden. Results from RACOMIP, a randomized controlled trial.
    Broberg G; Jonasson JM; Ellis J; Gyrd-Hansen D; Anjemark B; Glantz A; Söderberg L; Ryd ML; Holtenman M; Milsom I; Strander B
    Int J Cancer; 2013 Jul; 133(1):164-71. PubMed ID: 23233356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower cost strategies for triage of human papillomavirus DNA-positive women.
    Qiao YL; Jeronimo J; Zhao FH; Schweizer J; Chen W; Valdez M; Lu P; Zhang X; Kang LN; Bansil P; Paul P; Mahoney C; Berard-Bergery M; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
    Int J Cancer; 2014 Jun; 134(12):2891-901. PubMed ID: 24248915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cervical testing beyond the screening target age - A register-based cohort study from Finland.
    Keltto N; Leivonen A; Pankakoski M; Sarkeala T; Heinävaara S; Anttila A
    Gynecol Oncol; 2021 Aug; 162(2):315-321. PubMed ID: 34074539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic human papillomavirus infection and cervical lesions in aboriginal women of Nunavut, Canada.
    Healey SM; Aronson KJ; Mao Y; Schlecht NF; Mery LS; Ferenczy A; Franco EL
    Sex Transm Dis; 2001 Dec; 28(12):694-700. PubMed ID: 11725224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China.
    Zhao FH; Jeronimo J; Qiao YL; Schweizer J; Chen W; Valdez M; Lu P; Zhang X; Kang LN; Bansil P; Paul P; Mahoney C; Berard-Bergery M; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
    Cancer Prev Res (Phila); 2013 Sep; 6(9):938-48. PubMed ID: 23878179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Offering Cervical Cancer Screening with HPV Self-Sampling among African-American Women in the Mississippi Delta.
    Campos NG; Scarinci IC; Tucker L; Peral S; Li Y; Regan MC; Sy S; Castle PE; Kim JJ
    Cancer Epidemiol Biomarkers Prev; 2021 Jun; 30(6):1114-1121. PubMed ID: 33771846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.
    Schiffman M; Herrero R; Hildesheim A; Sherman ME; Bratti M; Wacholder S; Alfaro M; Hutchinson M; Morales J; Greenberg MD; Lorincz AT
    JAMA; 2000 Jan; 283(1):87-93. PubMed ID: 10632285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.